Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptimUM-10 darovasertib neoadjuvant phase 3 trial in primary non-metastatic uveal melanoma
MOH_2025-10-23_014400Phase 3Not yet recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darovasertib in intraocular melanoma (4 cohorts), sponsored by IDEAYA Biosciences. Primary endpoints: Rate of vision loss in Cohort 1 and Eye salvage / avoidance of enucleation in Cohort 2. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
darovasertib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on MOH_2025-10-23_014400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-23_014400.